Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
PD-L1
VISTA
biomarker
germ cell tumor
immunohistochemistry
inflammation
prognosis
testicular cancer
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Apr 2021
07 Apr 2021
Historique:
received:
28
01
2021
revised:
16
03
2021
accepted:
02
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
In the current study, we aimed to investigate whether expression of immune checkpoint proteins (V-domain Ig suppressor of T cell activation (VISTA) and programmed death-ligand 1 (PD-L1)) and markers of systemic inflammation could predict progression/relapse and death in the cohort of 180 patients with testicular germ-cell tumors (GCTs). Expression of PD-L1 and VISTA was assessed by immunohistochemistry utilizing tissue microarrays. To estimate systemic inflammation neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) were calculated. We found high PD-L1 and VISTA expression on tumor-associated immune cells (TAICs) in 89 (49.44%) and 63 (37.22%) of GCTs, respectively, whereas tumor cells besides trophoblastic elements were almost uniformly negative. High PD-L1 was associated with seminomatous histology and lower stage. Relapses in stage I patients occurred predominantly in cases with low numbers of PD-L1 and VISTA-expressing TAICs. In stage II/III disease, the combination of low VISTA-expressing TAICs and high PLR was identified as predictor of shorter event-free survival (HR 4.10; 1.48-11.36,
Identifiants
pubmed: 33916925
pii: cancers13081750
doi: 10.3390/cancers13081750
pmc: PMC8067539
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Gdański Uniwersytet Medyczny
ID : 01-0395/08/643
Références
Cell Mol Immunol. 2018 May;15(5):438-446
pubmed: 29375120
Int J Cancer. 2006 Aug 15;119(4):831-8
pubmed: 16557580
Transplantation. 2009 Jun 27;87(12):1778-86
pubmed: 19543053
Semin Cancer Biol. 2020 Dec 7;:
pubmed: 33301862
Histopathology. 2019 Sep;75(3):421-430
pubmed: 31013360
Oncol Lett. 2018 Jun;15(6):9852-9860
pubmed: 29928359
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817109
Cancer Immunol Immunother. 2020 Jan;69(1):33-42
pubmed: 31781843
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
Cancer Immunol Res. 2014 Jun;2(6):510-7
pubmed: 24894088
Int J Urol. 2019 Jan;26(1):31-47
pubmed: 30253448
Sci Rep. 2020 Jan 27;10(1):1243
pubmed: 31988315
Int Braz J Urol. 2016 Jan-Feb;42(1):53-9
pubmed: 27136467
J Res Med Sci. 2018 Jul 26;23:64
pubmed: 30181746
Ann Oncol. 2018 Aug 1;29(8):1658-1686
pubmed: 30113631
Onco Targets Ther. 2020 Jul 03;13:6475-6483
pubmed: 32753888
Lancet. 1964 Nov 21;2(7369):1102-4
pubmed: 14207903
Semin Immunol. 2019 Apr;42:101308
pubmed: 31604531
J Surg Case Rep. 2019 Jan 09;2019(1):rjy358
pubmed: 30647899
Clin Cancer Res. 2018 Apr 1;24(7):1562-1573
pubmed: 29203588
Ann Oncol. 2016 Feb;27(2):300-5
pubmed: 26598537
Oncoimmunology. 2018 Dec 13;8(2):e1542245
pubmed: 30713803
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Oncol Lett. 2019 Aug;18(2):1497-1502
pubmed: 31423216
N Engl J Med. 1999 Feb 11;340(6):448-54
pubmed: 9971870
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Br J Cancer. 2018 Jul;119(1):80-88
pubmed: 29921949
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Front Oncol. 2021 Jan 11;10:583966
pubmed: 33505908
Eur J Cancer. 2017 May;76:1-7
pubmed: 28262583
ESMO Open. 2020 Jun;4(Suppl 3):e000683
pubmed: 32554470
Ann Oncol. 2017 Apr 1;28(4):906-907
pubmed: 28039179
Eur J Immunol. 2017 Jul;47(7):1232-1242
pubmed: 28555838
Eur Urol. 2018 Mar;73(3):394-405
pubmed: 29100813
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Oncoimmunology. 2019 Feb 27;8(5):e1581546
pubmed: 31069143
Urol Oncol. 2021 Feb;39(2):136.e19-136.e25
pubmed: 33353868
Reprod Med Biol. 2019 Aug 29;19(1):24-31
pubmed: 31956282
Haematologica. 2018 Nov;103(11):1908-1914
pubmed: 30026337
Int J Urol. 2019 Aug;26(8):813-819
pubmed: 31115106
Actas Urol Esp. 2019 Jul - Aug;43(6):284-292
pubmed: 31085041
Am J Clin Pathol. 2020 Feb 8;153(3):387-395
pubmed: 31802108
J Immunother Cancer. 2018 Jan 22;6(1):5
pubmed: 29353553
Ann Oncol. 2018 Jan 1;29(1):209-214
pubmed: 29045540
Eur Urol. 2018 Apr;73(4):560-569
pubmed: 29325693
Cell Mol Immunol. 2014 Sep;11(5):428-37
pubmed: 24954222
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
World J Urol. 2004 Apr;22(1):2-14
pubmed: 15034740
Oncotarget. 2017 Mar 28;8(13):21794-21805
pubmed: 28423520
Front Oncol. 2020 Sep 24;10:573977
pubmed: 33072608
Biomed Res Int. 2017;2017:1506824
pubmed: 29318140
Investig Clin Urol. 2019 May;60(3):176-183
pubmed: 31098425
Clin Chim Acta. 2018 Aug;483:48-56
pubmed: 29678631
Science. 2020 Jan 17;367(6475):
pubmed: 31949051
Br J Cancer. 2015 Jul 28;113(3):411-3
pubmed: 26171934
Oncotarget. 2017 Dec 27;9(5):6201-6212
pubmed: 29464065
Cancers (Basel). 2019 Oct 11;11(10):
pubmed: 31614500
Eur Urol. 2019 Jan;75(1):201-203
pubmed: 30243800
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Anticancer Res. 2019 Dec;39(12):6851-6857
pubmed: 31810952
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7
pubmed: 25964334